Analyst Ratings for Reata Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Reata Pharmaceuticals (NASDAQ:RETA) has received a mix of bullish and indifferent analyst ratings in the last quarter. In the last 3 months, 13 analysts have offered 12-month price targets for the company, with an average price target of $149.92, a 42.78% increase from the previous average price target of $105.00.
August 15, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals has received mixed analyst ratings, with an average 12-month price target of $149.92, indicating a potential upside.
The average 12-month price target for Reata Pharmaceuticals has increased by 42.78% from the previous average, indicating a bullish sentiment among analysts. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100